Chinese biotech firm Innovent Biologics priced its Hong Kong initial public offering near the top of an indicative range, raising $421 million in the city’s largest biotech IPO this year, two sources familiar with the matter said.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
